Research programme: GABA A receptor inverse agonists - Merck Sharp & Dohme
Alternative Names: IAα5-2Latest Information Update: 29 Jan 2008
At a glance
- Originator Merck Sharp & Dohme
- Class Thiophenes
- Mechanism of Action GABA A alpha 5 receptor inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease
Most Recent Events
- 29 Jul 2004 Phase-I clinical trials in Alzheimer's disease in USA (unspecified route)
- 29 Jul 2004 Data presented at the 9th International Conference on Alzheimer's Disease and Related Disorders (ICAD-2004) have been added to the pharmacokinetics section
- 01 Jul 2003 Removed Research programme from the title